Purpose
During pre-vaccine era, pharmaceutical supplies [self-care essentials (SCEs)] have been proved to be a major deflector, protector and safety guard against novel coronavirus disease (COVID-19). Hence, the objective of the study is to provide a comprehensive socio-technological decision-making framework based on multiple criteria for selecting the suppliers of pharmaceuticals, such as SCEs, by multi-brand enterprises (distributors) in the pandemic environment.

Design/methodology/approach
A hybrid methodology of Bayesian best worst method (BWM) and multi-attributive border approximation area comparison (MABAC) method has been applied for carrying out the study. Bayesian BWM has been applied for computing the importance of criteria identified for the selection of SCEs' suppliers during pandemic environment and MABAC method evaluated the suppliers of the SCEs.

Findings
In the study, the authors have identified eight criteria such as disinfection and sanitization of vehicles, social conscience of suppliers, brand (Technological recognition) of SCEs and logistics and distribution network, among others, which are critical to the selection of a supplier for the supply of SCEs. The application of the proposed hybrid model revealed that lead time and quality of SCEs are of utmost concern for pharmacies in a pandemic environment. Among the ten suppliers, results showed that Suppliers 2, 4 and 5 have been ranked first for supplying hand wash, hand sanitizer and face mask, respectively.

Practical implications
The proposed model has helped the multi-brand distributors of pharmaceuticals in selecting suppliers during the ongoing crisis of COVID-19. In addition to that, in future the outcomes of the study would be helpful for multi-brand distributors as well as pharmacies and hospitals in selecting the best suppliers. Policy makers will be able to make and revise the policies immediately with the help of the proposed decision-making framework.

Originality/value
The paper makes a novel contribution towards theory with the criteria identified for selecting best suppliers during the pandemic COVID-19. Additionally, the proposed hybrid model helps multi-brand distributors of pharmaceuticals in making decisions that lead to a huge social and economic success in pandemic time.